New and experimental hepatitis C treatment: latest news

New and experimental hepatitis C treatment resources

New and experimental hepatitis C treatment features

New and experimental hepatitis C treatment news from aidsmap

More news

New and experimental hepatitis C treatment news selected from other sources

  • NHS England agrees funding for life-saving hepatitis C drug

    NHS England has approved an £18.7 million investment in a new drug for the treatment of hepatitis C. Around 500 patients with acute liver failure, and/or awaiting liver transplantation, are expected to benefit from the decision to fund Sofosbuvir.

    17 April 2014 | NHS England (press release)
  • England: Patients with end-stage liver disease caused by hepatitis C to get new drug

    The NHS is to pay for around 500 people with end-stage liver disease caused by hepatitis C to receive Sofosbuvir, a new drug which could cure them, without waiting for guidance from the advisory body, Nice.

    17 April 2014 | The Guardian
  • Egypt: New Treatments May Defuse Viral Hepatitis Time Bomb

    Egypt is said officially to have the highest prevalence of hepatitis C in the world, with 10 to 14 percent of its 85 million people infected, and about two million in dire need of treatment. The Egyptian government recently struck a deal with U.S. pharmaceutical firm Gilead Sciences to purchase its new hepatitis C pill Sovaldi at a fraction of its American price.

    10 April 2014 | Inter Press Service
  • Gilead aims to license hepatitis C drug to 3-4 Indian firms

    Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.

    09 April 2014 | Reuters
  • Gilead says has discounted hepatitis C drug for some health plans

    Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.

    31 March 2014 | Reuters
  • Gilead offers Egypt new hepatitis C drug at 99 percent discount

    Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price. While the drug will still cost $900 for a 12-week course of treatment, that is a fraction of the $84,000 charged for a course of treatment in the United States.

    24 March 2014 | Reuters
  • US Lawmakers Attack Cost of New Hepatitis Drug

    A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday.

    24 March 2014 | New York Times
  • Trouble Ahead for Gilead and Sovaldi?

    Atop ever-inflating sales estimates for Gilead Science's blockbuster Sovaldi, patent battles also continue to crop up. Late last week Idenix Pharmaceuticals added three more suits to the pile, filing in France, Germany and the UK for patent infringement on nucleosides, a precursor to the compound in Sovaldi. This is in addition to two lawsuits it has pending against Gilead stateside since late last year.

    19 March 2014 | Motley Fool
  • How Much Should Hepatitis C Treatment Cost?

    A new pill to treat hepatitis C raises difficult questions about fair pricing, not only in the United States and other affluent nations but in developing countries around the world.

    18 March 2014 | New York Times (editorial)
  • Hepatitis C treatments: Australia urged to subsidise 'revolutionary' new drugs

    Public health experts say effective new drugs to treat hepatitis C should be subsidised in Australia to avert a looming strain on the national health system.

    18 March 2014 | ABC Online
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.